CellSource Co (TSE:4880) Other Stockholders Equity: 円115 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4880 CellSource Co Ltd TSE:4880
69 GF Score
Price 円342.00
GF Value 円780.54
Valuation Significantly Undervalued
! 6 Warning Signs
View Full Analysis

What is CellSource Co Other Stockholders Equity?

CellSource Co TSE:4880 -0.29% 69 Other Stockholders Equity is 円115 Mil as of Apr. 2026. GuruFocus rates TSE:4880 with a GF Score™ of 69/100 and a GF Value™ of 円780.54 (Significantly Undervalued). The stock has 6 warning signs investors should review.

CellSource Co's Other Stockholders Equity for the quarter that ended in Apr. 2026 was 円115 Mil.

CellSource Co's quarterly Other Stockholders Equity increased from Apr. 2025 (円51 Mil) to Oct. 2025 (円121 Mil) but then declined from Oct. 2025 (円121 Mil) to Apr. 2026 (円115 Mil).

CellSource Co's annual Other Stockholders Equity declined from Oct. 2023 (円66 Mil) to Oct. 2024 (円56 Mil) but then increased from Oct. 2024 (円56 Mil) to Oct. 2025 (円121 Mil).

CellSource Co Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for CellSource Co's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellSource Co Other Stockholders Equity Chart

CellSource Co Annual Data
Trend Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 17.22 44.60 65.58 55.81 120.55

CellSource Co Semi-Annual Data
Oct17 Oct18 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25 Apr26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.40 55.81 51.00 120.55 114.64
TSE:4880
69GF Score
CellSource Co Ltd TSE:4880
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CellSource Co Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円115 Mil mean?
CellSource Co (TSE:4880) has a Other Stockholders Equity of 円115 Mil as of Apr. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CellSource Co and its competitors.
Is CellSource Co's Other Stockholders Equity too high?
CellSource Co's current Other Stockholders Equity is 円115 Mil. Overall, CellSource Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's Other Stockholders Equity compare to VRTX and REGN?
CellSource Co's Other Stockholders Equity of 円115 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on CellSource Co and its competitors. CellSource Co's current Other Stockholders Equity is 円115 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円780.54, compared to a current price of 円342.00 — trading 56.2% below its estimated fair value. The current Other Stockholders Equity is 円115 Mil. CellSource Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current Other Stockholders Equity is 円115 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellSource Co (TSE:4880) Overvalued in 2026?

Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued. The current stock price of 円342.00 is trading 56.2% below its estimated GF Value™ of 円780.54. GuruFocus considers CellSource Co to be Significantly Undervalued.

Key valuation signals for TSE:4880:

  • Other Stockholders Equity: 円115 Mil
  • GF Value™: 円780.54 vs. price of 円342.00 (56.2% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellSource Co Business Description

Address Shibuya Mitake Building, 2nd Floor, 1-19-5 Shibuya, Shibuya-ku, Tokyo, JPN, 150-0002
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
69GF Score

Get the complete analysis for TSE:4880

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円342.00
Price
円780.54
GF Value